Home
NLSP
NLSP News

Latest NLS Pharmaceutics Ltd. (NLSP) News on September 3, 2025

NLS Pharmaceutics CEO Issues Letter to Shareholders

PR Newswire

3 months ago

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

PR Newswire

3 months ago

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

MT Newswires

5 months ago

NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

PR Newswire

5 months ago

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

ACCESS Newswire

5 months ago

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

NLS Pharmaceutics CEO Issues Letter to Shareholders

PR Newswire

6 months ago

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

PR Newswire

6 months ago

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

PR Newswire

6 months ago

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

PR Newswire

7 months ago

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

MT Newswires

7 months ago

NLS Pharmaceutics Says Kadimastem Shareholders Approve Merger With NLS; Shares Rise

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

PR Newswire

7 months ago

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

PR Newswire

7 months ago

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

PR Newswire

7 months ago

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

PR Newswire

8 months ago

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

NLS Pharmaceutics and Kadimastem Advance Merger Plans with $500,000 Fundraising

TipRanks

8 months ago

NLS Pharmaceutics and Kadimastem Advance Merger Plans with $500,000 Fundraising

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025

PR Newswire

8 months ago

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

PR Newswire

8 months ago

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

ACCESSWIRE

8 months ago

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

NLS Pharmaceutics expects to close Kadimastem merger by end of January

TipRanks

9 months ago

NLS Pharmaceutics expects to close Kadimastem merger by end of January

NLS Pharmaceutics CEO Issues Letter to Shareholders

ACCESSWIRE

9 months ago

NLS Pharmaceutics CEO Issues Letter to Shareholders

MT Newswires

9 months ago

NLS Pharmaceutics Prices Up to $1 Million Private Placement

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

PR Newswire

9 months ago

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

ACCESSWIRE

9 months ago

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

ACCESSWIRE

10 months ago

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

NLS and Kadimastem stocks soar following merger agreement

Pharmaceutical Technology

10 months ago

NLS and Kadimastem stocks soar following merger agreement

NLS Pharmaceutics, Kadimastem enter definitive merger agreement

TipRanks

10 months ago

NLS Pharmaceutics, Kadimastem enter definitive merger agreement

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

ACCESSWIRE

10 months ago

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

ACCESSWIRE

10 months ago

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

ACCESSWIRE

10 months ago

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges

TipRanks

10 months ago

NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules

ACCESSWIRE

a year ago

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

ACCESSWIRE

a year ago

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

MT Newswires

a year ago

NLS Pharmaceutics Signs Binding Term Sheet for Merger With Kadimastem; Shares Rise

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

ACCESSWIRE

a year ago

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

MT Newswires

a year ago

NLS Pharmaceutics Announces Registered Direct Offering, Private Placement of Shares, Warrants

NLS Pharmaceutics Announces Registered Direct Offering

ACCESSWIRE

a year ago

NLS Pharmaceutics Announces Registered Direct Offering

MT Newswires

a year ago

Top Midday Gainers

MT Newswires

a year ago

NLS Pharmaceutics Reports Preclinical Data for Potential Parkinson's Disease Treatments; Shares Jump

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

ACCESSWIRE

a year ago

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements

ACCESSWIRE

a year ago

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements

NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

ACCESSWIRE

a year ago

NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model

ACCESSWIRE

a year ago

NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq

ACCESSWIRE

a year ago

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

ACCESSWIRE

a year ago

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

ACCESSWIRE

a year ago

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

ACCESSWIRE

a year ago

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

ACCESSWIRE

a year ago

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

ACCESSWIRE

a year ago

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance

ACCESSWIRE

a year ago

Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

ACCESSWIRE

2 years ago

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

When 2 Million Is Not Enough: ECD Auto Design Unveils Cutting-Edge Web Configurator for Custom Vehicles

PR Newswire

2 years ago

When 2 Million Is Not Enough: ECD Auto Design Unveils Cutting-Edge Web Configurator for Custom Vehicles

Round Table Pizza Shares the Love on National Pizza Day and Valentine’s Day with Sweet Deals

GlobeNewswire

2 years ago

Round Table Pizza Shares the Love on National Pizza Day and Valentine’s Day with Sweet Deals

Reuters

2 years ago

TABLE-LNG tankers heading to Britain, Belgium, the Netherlands and Germany

Reuters

2 years ago

UPDATE 4-Texas Freeport LNG unit faces month-long outage after winter storm

Reuters

2 years ago

UPDATE 3-Biden pauses LNG export approvals after pressure from climate activists

BP Eyes FID for Trinidad's Calypso Deepwater Gas Field by 2025

Zacks

2 years ago

BP Eyes FID for Trinidad's Calypso Deepwater Gas Field by 2025

Reuters

2 years ago

GLOBAL LNG-Asia spot prices remain flat below $10/mmBtu despite geopolitical risks

Biogas Traders Become Hot Commodities on Demand for Clean Fuel

Bloomberg

2 years ago

Biogas Traders Become Hot Commodities on Demand for Clean Fuel

Phunware Announces Pricing of $5.6 Million Registered Direct Offering

GlobeNewswire

2 years ago

Phunware Announces Pricing of $5.6 Million Registered Direct Offering

SPECTAIRE ANNOUNCES THE COMPLETION OF THE FORWARD PURCHASE AGREEMENT WITH METEORA FUNDS

PR Newswire

2 years ago

SPECTAIRE ANNOUNCES THE COMPLETION OF THE FORWARD PURCHASE AGREEMENT WITH METEORA FUNDS

5E Advanced Materials Announces Stockholder Approval of Proposed Out of Court Restructuring

GlobeNewswire

2 years ago

5E Advanced Materials Announces Stockholder Approval of Proposed Out of Court Restructuring

Notice of Deficiency with Nasdaq Continued Listing Requirements

ACCESSWIRE

2 years ago

Notice of Deficiency with Nasdaq Continued Listing Requirements

Casa Systems Named “Global IoT Innovation Vendor of the Year” in 8ᵗʰ Annual IoT Breakthrough Awards Program

GlobeNewswire

2 years ago

Casa Systems Named “Global IoT Innovation Vendor of the Year” in 8ᵗʰ Annual IoT Breakthrough Awards Program

Emcore (EMKR) Is Attractively Priced Despite Fast-paced Momentum

Zacks

2 years ago

Emcore (EMKR) Is Attractively Priced Despite Fast-paced Momentum

Business Wire

2 years ago

AtlasClear Announces the Extension of Business Combination Agreement with Quantum FinTech Acquisition Corporation and the Restructuring of its Proposed Acquisition of Wilson-Davis & Co, Inc.

Tritium Unveils Autocharge Software Capability for RTM and PKM Chargers; Partner Lynkwell Leads on Implementation of Innovative Feature

GlobeNewswire

2 years ago

Tritium Unveils Autocharge Software Capability for RTM and PKM Chargers; Partner Lynkwell Leads on Implementation of Innovative Feature

Q3 Earnings Highs And Lows: Amplitude (NASDAQ:AMPL) Vs The Rest Of The Data Analytics Stocks

StockStory

2 years ago

Q3 Earnings Highs And Lows: Amplitude (NASDAQ:AMPL) Vs The Rest Of The Data Analytics Stocks

Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

GlobeNewswire

2 years ago

Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

Assertio Holdings, Inc. Announces Leadership Transition

GlobeNewswire

2 years ago

Assertio Holdings, Inc. Announces Leadership Transition

Modiv Industrial Declares Distribution of GIPR Common Shares

Business Wire

2 years ago

Modiv Industrial Declares Distribution of GIPR Common Shares

NLS Pharmaceutics CEO Issues Letter to Shareholders

ACCESSWIRE

2 years ago

NLS Pharmaceutics CEO Issues Letter to Shareholders

Expion360 Announces Leadership Transition with Planned Retirement of Co-Founder John Yozamp

ACCESSWIRE

2 years ago

Expion360 Announces Leadership Transition with Planned Retirement of Co-Founder John Yozamp

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

PR Newswire

2 years ago

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Simply Wall St.

2 years ago

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Sezzle Board of Directors Authorizes US$5 Million Stock Repurchase Program

GlobeNewswire

2 years ago

Sezzle Board of Directors Authorizes US$5 Million Stock Repurchase Program

PodcastOne (NASDAQ: PODC) Acquires Exclusive Rights to Hit Podcast Was I In A Cult? From Hosts Liz Iacuzzi and Tyler Measom

GlobeNewswire

2 years ago

PodcastOne (NASDAQ: PODC) Acquires Exclusive Rights to Hit Podcast Was I In A Cult? From Hosts Liz Iacuzzi and Tyler Measom

Are Investors Undervaluing Vertex Energy, Inc. (NASDAQ:VTNR) By 41%?

Simply Wall St.

2 years ago

Are Investors Undervaluing Vertex Energy, Inc. (NASDAQ:VTNR) By 41%?

Expion360 Enters Home Energy Storage Market with All-in-One and Scalable Lithium-ion Battery Solutions

ACCESSWIRE

2 years ago

Expion360 Enters Home Energy Storage Market with All-in-One and Scalable Lithium-ion Battery Solutions

Red Cat Holdings Reports Financial Results for Fiscal Second Quarter 2024 and Provides Corporate Update

GlobeNewswire

2 years ago

Red Cat Holdings Reports Financial Results for Fiscal Second Quarter 2024 and Provides Corporate Update

We Think VirnetX Holding (NYSE:VHC) Needs To Drive Business Growth Carefully

Simply Wall St.

2 years ago

We Think VirnetX Holding (NYSE:VHC) Needs To Drive Business Growth Carefully

Brainsway Ltd. Sponsored ADR (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

2 years ago

Brainsway Ltd. Sponsored ADR (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why

Investing.com

2 years ago

Midday movers: Adobe, Moderna, and more

Mesa Air Group Announces Intent to File Form 12b-25 and Delay Its Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call

GlobeNewswire

2 years ago

Mesa Air Group Announces Intent to File Form 12b-25 and Delay Its Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

GlobeNewswire

2 years ago

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Top Ships Announces Increase From Previously Announced Management Estimate of Net Asset Value to $344 Million and Contracted Revenue Backlog of $400 Million

GlobeNewswire

2 years ago

Top Ships Announces Increase From Previously Announced Management Estimate of Net Asset Value to $344 Million and Contracted Revenue Backlog of $400 Million

Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing

GlobeNewswire

2 years ago

Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing

eHealth, Inc.'s (NASDAQ:EHTH) high institutional ownership speaks for itself as stock continues to impress, up 10% over last week

Simply Wall St.

2 years ago

eHealth, Inc.'s (NASDAQ:EHTH) high institutional ownership speaks for itself as stock continues to impress, up 10% over last week

Zentek and 1Click Heating and Cooling Sign Distribution Agreement

ACCESSWIRE

2 years ago

Zentek and 1Click Heating and Cooling Sign Distribution Agreement

TOP Ships Announces Increase in Shareholding by Pistiolis Family to 73% Via Full Conversion of Preferred Shares and Open-Market Purchases Demonstrating the CEO’S Commitment to the Company

GlobeNewswire

2 years ago

TOP Ships Announces Increase in Shareholding by Pistiolis Family to 73% Via Full Conversion of Preferred Shares and Open-Market Purchases Demonstrating the CEO’S Commitment to the Company

Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

PR Newswire

2 years ago

Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

Thomson Reuters StreetEvents

2 years ago

Q2 2024 Barnes & Noble Education Inc Earnings Call

Associated Press Finance

2 years ago

Barnes & Noble Education: Fiscal Q2 Earnings Snapshot

Hongli Group Inc. (NASDAQ:HLP) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Simply Wall St.

2 years ago

Hongli Group Inc. (NASDAQ:HLP) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Business Wire

2 years ago

Vince Holding Corp. Reports Third Quarter 2023 Results

InspireMD's Gary Roubin Acquires 13% More Stock

Simply Wall St.

2 years ago

InspireMD's Gary Roubin Acquires 13% More Stock

Sidoti Events, LLC's Virtual December Small-Cap Conference

ACCESSWIRE

2 years ago

Sidoti Events, LLC's Virtual December Small-Cap Conference

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 years ago

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Best Debt Free Penny Stocks To Buy Now

Insider Monkey

2 years ago

10 Best Debt Free Penny Stocks To Buy Now

Top Penny Stocks for Q4 2023

Investopedia

2 years ago

Top Penny Stocks for Q4 2023

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

ACCESSWIRE

2 years ago

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

Share on Social Networks: